Type II Polyglandular Autoimmune Syndrome Follow-up
- Author: Surendra Sivarajah, MD; Chief Editor: Romesh Khardori, MD, PhD, FACP more...
Further Inpatient Care
Continuously screen patients who have had fewer than all 3 diseases every 1-2 years, until they are aged 50 years. This detects new disorders before overt clinical features develop. Screening should include an assessment of autoantibodies, electrolytes, thyroid function tests, liver function tests, vitamin B-12 levels, Cortrosyn-stimulation test, fasting blood glucose, plasma renin activity, CBCs, gonadotropins, and testosterone/estradiol. In females who have regular menses, gonadotropins and estradiol are not necessary.
Evaluate patients for asplenia, and administer pneumococcal and flu vaccinations.
Family members should be strongly considered for genetic counseling and should undergo necessary screening for autoimmune diseases.
All patients with adrenal insufficiency should wear emergency identification bracelets, because adrenal crises are a significant cause of preventable mortality in these individuals. Bracelets should indicate whether the patient also has diabetes, because the coexistence of adrenal failure increases the risk of hypoglycemia.
Patients committed to the lifelong use of minerals, vitamins, blood work, and hormonal replacement therapy require psychosocial support.
The mortality and morbidity rates associated with polyglandular autoimmune syndrome type II (PGA-II) are assumed to be identical to those of the component diseases when these disorders occur in isolation.
Inpatient & Outpatient Medications
Administer specific hormone replacement as necessary (eg, T4, corticosteroids, sex steroids, insulin), depending on which endocrine end-organ failures have occurred.
Complications are related to the underlying endocrine organ failure, ie, complications of diabetes in autoimmune insulitis/diabetes.
See Further Inpatient Care.
If autoimmune destruction of the pancreas occurs, provide extensive diabetes education for the patient. The same is true for the thyroid and other aspects.
The genetic predisposition of polyglandular autoimmune syndrome type II (PGA-II) requires educating other family members regarding testing.
For patient education resources, see the Endocrine System Center; Diabetes Center; Esophagus, Stomach, and Intestine Center; and Blood and Lymphatic System Center, as well as Thyroid Problems, Diabetes, Celiac Sprue, and Anemia.
Obermayer-Straub P, Manns MP. Autoimmune polyglandular syndromes. Baillieres Clin Gastroenterol. 1998 Jun. 12(2):293-315. [Medline].
Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N Engl J Med. 2004 May 13. 350(20):2068-79. [Medline].
Baker JR Jr. Autoimmune endocrine disease. JAMA. 1997 Dec 10. 278(22):1931-7. [Medline].
Ramos-Lopez E, Lange B, Kahles H, et al. Insulin gene polymorphisms in type 1 diabetes, Addison's disease and the polyglandular autoimmune syndrome type II. BMC Med Genet. 2008 Jul 11. 9:65. [Medline]. [Full Text].
Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev. 2003 May. 2(3):119-25. [Medline].
Borgaonkar MR, Morgan DG. Primary biliary cirrhosis and type II autoimmune polyglandular syndrome. Can J Gastroenterol. 1999 Nov. 13(9):767-70. [Medline].
de Graaff LC, Smit JW, Radder JK. Prevalence and clinical significance of organ-specific autoantibodies in type 1 diabetes mellitus. Neth J Med. 2007 Jul-Aug. 65(7):235-47. [Medline].
Förster G, Krummenauer F, Kühn I, et al. [Polyglandular autoimmune syndrome type II: epidemiology and forms of manifestation]. Dtsch Med Wochenschr. 1999 Dec 10. 124(49):1476-81. [Medline].
Bizzaro N. The predictive significance of autoantibodies in organ-specific autoimmune diseases. Clin Rev Allergy Immunol. 2008 Jun. 34(3):326-31. [Medline].
Rakel RE, ed. Conn's Current Therapy. Philadelphia, Pa: Saunders; 1999. 630-54.
Cooper DS, Rivkees SA. Putting propylthiouracil in perspective. J Clin Endocrinol Metab. 2009 Jun. 94(6):1881-2. [Medline].
Eisenbarth G, Verge C. Immunoendocrinopathy syndromes. Wilson JD, ed. Williams Textbook of Endocrinology. 9th ed. Philadelphia, Pa: Saunders; 1998. 1651-9.
Lachmann PJ, Rosen F. Autoimmune endocrine disease. Lachmann PJ, ed. Clinical Aspects of Immunology. 5th ed. Boston, Mass: Blackwell Scientific Pubs; 1993. 2001-2.
Muir A, Katz D, McClaren N. Polyglandular failure syndromes. DeGroot LJ, ed. DeGroot's Endrocrinology. 3rd ed. Philadelphia, Pa: Saunders; 1995. 3013-22.
US Food and Drug Administration. Information for Healthcare Professionals - Propylthiouracil-Induced Liver Failure. US Department of Health and Human Services. Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm162701.htm. Accessed: April 9, 2013.